 Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis voclosporin will be approved for lupus nephritis in the European territories. About 21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if Omicron variant doesnt resurge, then its possible sales could improve further. 